Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14747.

Sethi S, D'Agati VD, Nast CC, Fogo AB, De Vriese AS, Markowitz GS, et al. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int. 2017;91(4):787-789.

Rooper LM, Onenerk M, Siddiqui MT, Faquin WC, Bishop JA, Ali SZ. Nodular oncocytic hyperplasia: Can cytomorphology allow for the preoperative diagnosis of a nonneoplastic salivary disease? Cancer Cytopathol. 2017;125(8):627-634.

Simon MS, Westblade LF, Dziedziech A, Visone JE, Furman RR, Jenkins SG, et al. Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia. Clin Infect Dis. 2017;65(7):1222-1225.

Graff RE, Judson G, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, et al. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG. Prostate. 2017;77(6):647-653.

Magro CM, Olson LC, Fulmer CG. CD30+ T cell enriched primary cutaneous CD4+ small/medium sized pleomorphic T cell lymphoma: A distinct variant of indolent CD4+ T cell lymphoproliferative disease. Ann Diagn Pathol. 2017;30:52-58.

Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, et al. Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell. 2017;32(6):792-806.e7.

Tsang HC, Mathew S, Magro CM. An Aggressive Primary Cutaneous Follicle Center Lymphoma With c-MYC Translocation and CDKN2A (9p21) Deletion: A Case Report and Review of the Literature. Am J Dermatopathol. 2017;39(3):e44-e49.

Cheng E, Ko D, Nguyen M, Moo T-, Andreopoulou E, Hoda SA, et al. Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients. Am J Surg Pathol. 2017;41(9):1275-1282.

Sederdahl BK, Yi J, Jerris R, Gillespie SE, Westblade L, Kraft CS, et al. The Residual Vaccine-preventable Burden of Rotavirus Disease. Pediatr Infect Dis J. 2017;36(8):780-781.